Fremanezumab: Real-World Relief for Tough Migraine Cases

Research Summary

The PEARL Phase 4 study, published in Cephalalgia, explored the real-world effectiveness of fremanezumab for migraine prevention in patients with at least three prior preventive treatment failures. Analyzing 398 participants, the study found that 54% experienced a reduction of 50% or more in monthly migraine days within six months of starting fremanezumab. Specifically, 67% with episodic migraine and 47% with chronic migraine achieved this reduction. The safety profile was consistent with previous research. These results align with previous randomized controlled trials, highlighting fremanezumab's effectiveness and safety in real-world settings for challenging migraine cases.

Study Details

📄 Title: Addressing unmet needs in migraine: Real-world fremanezumab effectiveness in participants of the PEARL study with at least three prior preventive treatment failures.

👥 Research Team: Ashina M et al.

📚 Published In: Cephalalgia

📅 Publication Date: 2025 Dec

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.